Navigation Links
arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
Date:9/12/2013

BREDA, the Netherlands and GHENT, Belgium, September 12, 2013 /PRNewswire/ --

  • Breakthrough data to be presented during the 'Discovery on Target' conference in Boston, MA, USA on September 23, 2013

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has successfully generated potent antibody antagonists of Nav1.7, using its proprietary SIMPLE Antibody™ technology.

Nav1.7 has been thoroughly validated as a therapeutic target in chronic pain, yet no antibody-based antagonists have been developed to date. Drugs targeting ion channels such as Nav1.7 require exquisite target selectivity and specificity to avoid unwanted side effects, which makes antibodies a preferred and highly desirable class of drug.

Using the SIMPLE Antibody™ platform, arGEN-X scientists have isolated a diverse panel of human Nav1.7-specific antibodies that possess such selectivity and lack cross-reactivity with related Nav family members. Several antibody candidates tested in in vitro electrophysiology assays have been shown to potently antagonize the function of the channel. Further specificity analysis reveals a subset of functional antibody clones capable of recognizing the rodent ortholog of the target, enabling in vivo pharmacology studies.

arGEN-X's Nav1.7 research program has been supported by a grant of €1.3 million awarded by the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT), specifically to enable arGEN-X to leverage SIMPLE Antibody™ into challenging disease targets.

"This is a very important antibody discovery success for arGEN-X" said Hans de Haard, Ph.D., Chief Scientific Officer of arGEN-X. "By delivering potent antagonists of a target as complex as Nav1.7, SIMPLE Antibody&
'/>"/>

SOURCE arGEN-X
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
2. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
3. New Approach to Celiac Testing Identifies More Patients at Risk
4. SecureState Identifies Top 5 Vulnerabilities Facing Hospitals and Medical Device Manufactures
5. Runners Evaluation Identifies And Corrects Mechanical Deficits
6. Pfizer Identifies Synexus South African Clinical Research Sites as INSPIRE Sites - First in Africa
7. Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
8. Specific Technologies Detects and Identifies Potential Bioterrorism Pathogenic Bacteria
9. New Study Identifies Better Solution for Itch
10. Endexx identifies core platform for Medical Marijuana Industry
11. Millennium Research Group Identifies the Top Ten Trends in Medical Device Markets for 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... a privately held medical device company, announced today that ... ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to sell ... cancer in Japan . ViewRay,s technology, ... only MRI-guided radiation therapy system that images and treats ...
(Date:1/22/2015)... Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" ... on Omega-3 therapies for cardiovascular disease and overall health is ... accomplishments in 2014 and its outlook for 2015 from the ... Shareholders, We would like to take this opportunity ...
(Date:1/22/2015)... , Jan. 22, 2015 Increasing sophistication among enterprise ... of localization purchasing in 2015, says Moravia ... a recent study by market research firm Common Sense ... solution for their translation and localization needs. "From a ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... the launch of the endogo® HD, a mobile medical ... , The endogo® HD is a breakthrough device ... novel, web application; allowing physician-to-patient sharing, synchronization of patient ... secured connection to a referring doctor, anytime, anywhere. , ...
... Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD ... Ph.D., to the Company,s board of directors. Dr. Keltner ... a privately-held biotechnology company developing a late-stage, light-activated therapy ... also CEO of EPISTAT, an international healthcare technology transfer, ...
Cached Medicine Technology:Envisionier Announces the Launch of the endogo(R) HD, a Mobile Medical Imaging Platform for Capturing, Storing, and Sharing Endoscopic Multimedia 2Raptor Pharmaceutical Expands Board of Directors 2Raptor Pharmaceutical Expands Board of Directors 3Raptor Pharmaceutical Expands Board of Directors 4Raptor Pharmaceutical Expands Board of Directors 5
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television host, ... 32nd Annual Miami Breast Cancer Conference planned and ... , shares that “a fast-growing, virulent” cancer in her ... not followed up her clean mammogram with an ultrasound. ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 As interest ... overall health care gains momentum worldwide, Rev. Eric J. ... HealthCare Chaplaincy Network (HCCN), will be the keynote speaker ... care in Israel’s public health system. , The conference, “Hope ...
(Date:1/22/2015)... Step into a macabre world where plants hold ... Wicked Plants, the Museum’s latest featured exhibition, opens Saturday, ... and diabolical plants inside of a dilapidated, Victorian home. ... physical and neurological processes between botanicals and the human ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... CUR) updated the progress of its ongoing Phase I ... cells in the treatment of ALS (amyotrophic lateral sclerosis, ... Georgia. The company announced that, after reviewing the safety ... received injections in the lumbar region of the spine ...
... In line with the Europe 2020 strategy and its ... is to discuss international R&D&I cooperation activities and how ... SMEs and enhancing smart growth in the regions. ... to actively contribute to the conference,s discussions which will ...
... particular form of leukemia or cancer of the bone marrow, ... some cases this medicine has no effect. Researchers at ... of Peter Carmeliet, have investigated the role of placental growth ... factor increases the life expectancy of these mice, even in ...
... stamina and carry out cardiopulmonary resuscitation more effectively than ... have undergone extreme exertion. Their life-saving efforts may be ... conclusion of research carried out at the University of ... lifeguards are trained in, and regularly practice, rescue from ...
... HealthDay Reporter , MONDAY, June 13 (HealthDay News) -- ... people with diabetes are at greater risk of having another ... But, aggressively lowering cholesterol can help reduce that risk, the ... and who have diabetes are at higher risk of having ...
... Chase Cancer Center, one of the nation,s leading cancer ... into an agreement with Life Technologies Corporation that will ... of solid tumors. The agreement is a foundational ... Chase, a facility that will foster new discoveries and ...
Cached Medicine News:Health News:Neuralstem updates clinical trial progress 2Health News:Toward a more efficient therapy for a specific form of leukemia 2Health News:Extreme exertion does not impair the quality of CPR given by lifeguards 2Health News:Extreme exertion does not impair the quality of CPR given by lifeguards 3Health News:Diabetics May Be at Greater Risk for Second Stroke 2Health News:Diabetics May Be at Greater Risk for Second Stroke 3Health News:Fox Chase Cancer Center signs agreement with Life Technologies Corp. 2Health News:Fox Chase Cancer Center signs agreement with Life Technologies Corp. 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: